{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:33:57Z","timestamp":1790818437671,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":212,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["Unrestricted Grant"],"award-info":[{"award-number":["Unrestricted Grant"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1111\/jth.15415","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T06:23:37Z","timestamp":1622528617000},"page":"2322-2334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD\u2010AF Registry"],"prefix":"10.1016","volume":"19","author":[{"given":"Frank","family":"Cools","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Camm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Pierre","family":"Bassand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W.A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tsiatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fitzmaurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Misselwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.G.","family":"Turpie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15415_bb0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta\u2010analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1111\/jth.15415_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio\u2010thoracic surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.15415_bb0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/eurheartj\/ehx730","article-title":"Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD\u2010AF registry","volume":"39","author":"Verheugt","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.15415_bb0025","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real\u2010life atrial fibrillation patients: a report from the Euro heart survey on atrial fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.15415_bb0030","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"Fang","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1111\/jth.15415_bb0035","first-page":"596","article-title":"Discontinuation\/Interruption of warfarin therapy in patients with nonvalvular atrial fibrillation","volume":"21","author":"Spivey","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1111\/jth.15415_bb0040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15415_bb0045","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15415_bb0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15415_bb0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15415_bb0060","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/europace\/euv421","article-title":"Real\u2010world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation","volume":"18","author":"Beyer\u2010Westendorf","year":"2016","journal-title":"Europace"},{"key":"10.1111\/jth.15415_bb0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2017.07.793","article-title":"Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation","volume":"70","author":"Paquette","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15415_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non\u2010vitamin K antagonist oral anticoagulants","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15415_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ahj.2020.04.016","volume":"226","author":"Jackson","year":"2020","journal-title":"Am Heart J"},{"key":"10.1111\/jth.15415_bb0080","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta\u2010analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1111\/jth.15415_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: global anticoagulant registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"10.1111\/jth.15415_bb0090","first-page":"114","article-title":"Evolving quality standards for large\u2010scale registries: the GARFIELD\u2010AF experience","volume":"3","author":"Fox","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1111\/jth.15415_bb0095","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/biom.12845","article-title":"Modeling survival distribution as a function of time to treatment discontinuation: a dynamic treatment regime approach","volume":"74","author":"Yang","year":"2018","journal-title":"Biometrics"},{"key":"10.1111\/jth.15415_bb0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15415_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1111\/jth.15415_bb0110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15415_bb0115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/heartjnl-2016-310672","article-title":"Early non\u2010persistence with dabigatran and rivaroxaban in patients with atrial fibrillation","volume":"103","author":"Jackevicius","year":"2017","journal-title":"Heart"},{"key":"10.1111\/jth.15415_bb0120","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"Rivera\u2010Caravaca","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15415_bb0125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration","volume":"167","author":"Shore","year":"2014","journal-title":"Am Heart J"},{"key":"10.1111\/jth.15415_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1111\/jth.15415_bb0135","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real\u2010world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jth.15415_bb0140","doi-asserted-by":"crossref","first-page":"h246","DOI":"10.1136\/bmj.h246","article-title":"The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study","volume":"350","author":"Jun","year":"2015","journal-title":"BMJ"},{"key":"10.1111\/jth.15415_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/rth2.12188","article-title":"Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: more than just bleeding?","volume":"3","author":"Gutierrez","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.15415_bb0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2015.09.006","article-title":"Paroxysmal atrial fibrillation and the hazards of under\u2010treatment","volume":"202","author":"Aronis","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1111\/jth.15415_bb0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1160\/TH4-04-0383","article-title":"Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study","volume":"112","author":"Martinez","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15415_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031342","article-title":"Discontinuation of non\u2010vitamin K antagonist oral anticoagulants in patients with non\u2010valvular atrial fibrillation: a population\u2010based cohort study using primary care data from the health improvement network in the UK","volume":"9","author":"Ruigomez","year":"2019","journal-title":"BMJ Open"},{"key":"10.1111\/jth.15415_bb0165","first-page":"e1","article-title":"Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation","volume":"22","author":"Kachroo","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1111\/jth.15415_bb0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"Forslund","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.15415_bb0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/phar.2046","article-title":"Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the french national health care databases","volume":"38","author":"Maura","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jth.15415_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011427","article-title":"Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"8","author":"Hernandez","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1111\/jth.15415_bb0185","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.3390\/jcm9103274","article-title":"Indications and outcome in patients undergoing left atrial appendage closure\u2010the Austrian LAAC registry","volume":"9","author":"Zweiker","year":"2020","journal-title":"J Clin Med"},{"key":"10.1111\/jth.15415_bb0190","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1\u2010Year follow\u2010up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1111\/jth.15415_bb0195","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/europace\/euv069","article-title":"Scientific initiative committee EHRA. Left atrial appendage closure\u2010indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey","volume":"17","author":"Pison","year":"2015","journal-title":"Europace"},{"key":"10.1111\/jth.15415_bb0200","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15415_bb0205","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high\u2010risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15415_bb0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40256-016-0171-6","article-title":"A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation","volume":"16","author":"Obamiro","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1111\/jth.15415_bb0215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","volume":"61","author":"Patel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15415_bb0220","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3389\/fneur.2018.01095","article-title":"Impact of non\u2010vitamin K antagonist oral anticoagulant withdrawal on stroke outcomes","volume":"9","author":"Park","year":"2018","journal-title":"Front Neurol"},{"key":"10.1111\/jth.15415_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1111\/jth.15415_bb0230","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1161\/CIRCULATIONAHA.112.129759","article-title":"An update on the prognosis of patients with atrial fibrillation","volume":"126","author":"McManus","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jth.15415_bb0235","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.111.962688","article-title":"Atrial fibrillation and mortality in heart failure: a community study","volume":"4","author":"Chamberlain","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1111\/jth.15415_bb0240","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/jth.15415_bb0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/europace\/eur241","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options\u2013a report from the 3rd atrial fibrillation competence NETwork\/European heart rhythm association consensus conference","volume":"14","author":"Kirchhof","year":"2012","journal-title":"Europace"},{"key":"10.1111\/jth.15415_bb0250","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/jth.15415_bb0255","doi-asserted-by":"crossref","first-page":"h5876","DOI":"10.1136\/bmj.h5876","article-title":"Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study","volume":"351","author":"Staerk","year":"2015","journal-title":"BMJ"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622018840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622018840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:32:16Z","timestamp":1761535936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622018840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1538783622018840"],"URL":"https:\/\/doi.org\/10.1111\/jth.15415","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD\u2010AF Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}